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Abstract
Intrauterine devices (IUDs) represent one of the most important methods used for con-
traception. The methods vary in terms of efficiency, acceptability, costs, and potential 
complications. Early methods have been improved, and ultrasound (US) evaluation has 
become an important tool to diagnose the clear majority of IUDs complications. This 
chapter presents a comprehensive and up-to-date status regarding the use of intrauterine 
devices (IUDs) for birth control and family planning. The topics discussed in the manu-
script will involve the current knowledge on the history, types, mechanisms, health ben-
efits, and risks. More, the present paper presents the medical techniques for inserting and 
removing a IUD, and the role of US to confirm proper IUD placement. Also, this chapter 
offers practical guidance in managing problems of continuing users and discusses the 
clinical circumstances that require reconsideration of the contraception methods.
Keywords: intrauterine device, copper intrauterine device, hormonal intrauterine 
device, contraception, family planning, ultrasound
1. Introduction
Intrauterine devices (IUDs) represent long-lasting reversible birth control method [1] with 
the greatest satisfaction among users [2]. However, this contraceptive use generated much 
heated discussion and debates, with exhaustive studies that are presented in the present 
chapter.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. History of IUDs
Intrauterine contraception with various devices seems to have a long history, from the 
ancient Arabs who placed round smooth stones in the camels’ uteri to prevent conception 
during long journeys. In the late nineteenth century, intracervical devices have been used to 
prevent pregnancy or to induce abortion [3]. Still, the first medical communication on medi-
cal IUD was published in Germany, at the beginning of the twentieth century by Richter [4], 
who reported the results of intrauterine insertion of a metallic ring with catgut tied around 
it. In the 1920s, Ernest Graefenberg attached a silver wire to the ring for Roentgen visualiza-
tion, but silver rings were rapidly abandoned as they led to gingival argyrosis. An alloy of 
copper, nickel, and zinc was used instead [5]. In 1959, the first paper was published who 
condemned the IUDs as dangerous because of the ineffectiveness, risk of infection, and car-
cinogenic potential [5]. The modern IUDs evolved from 1960 with a T-shaped product that 
configured better to the natural shape of the uterus [6]. By the mid-1960s, IUDs became a 
widely used method with fewer potential cardiovascular risks when compared to oral con-
traceptives [7]. In 1970, nearly 10% of women were using the Dalkon Shield IUD as a con-
traceptive method. Since then, the use of IUDs dropped because of the severe septic cases 
reported, along with the increased risk of pelvic inflammatory disease (PID) and infertility 
[8]. IUDs were even withdrawn from the US market between 1986 and 1988.
Since the introduction of the levonorgestrel 52 mg IUD in 2001, this intervention achieved 
a new, therapeutic, dimension—because of significant benefits in treating heavy menstrual 
bleeding and dysmenorrhea [7].
Today, IUDs are an important component of family planning, as they are used by one in 10 
women in the USA and 9–24% of all contraceptives in European countries [9]. The highest 
rates of IUD use are recorded in Asia: 40% of women in China, 50% in Korea, and 56% in 
Uzbekistan [10], while the lowest rates are recorded in Africa. The trend of contraceptive 
method is declining as the use of injectable products is increasing [11]. From the begin-
ning, the gynecologists were preferred for a safe insertion of the IUD, instead of general 
practitioners [3].
3. Types of IUDs: copper and hormonal
The two main types of IUDs are the copper non-hormonal device and the hormonal device.
There are a few types of copper devices as well. The most frequent copper device series are the 
T380 devices that also consist of the original T380A, the T380Ag available in Finland, and the 
T380S available in Canada and UK [12]. This IUD has a small plastic “T” frame with a stem 
wrapped with copper wire and also copper collars on the two arms of the frame, of about 
380 mm2 of copper. T380A has been approved around the world for up to 10 years [13], with 
no uterine perforation reported, but a high rate of medical removal due to bleeding, pain, and 
pelvic infection [12].
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Other types of copper IUDs include the Multiload series of devices that consists of ML250 for 
a 3 years’ use and the ML375 with more copper to enhance a longer use, up to 5 years. The 
device has additional plastic fins on the lateral, and curved arms to avoid spontaneous expul-
sion [12].
The GyneFix device has been introduced in 1997 as a frameless copper-bearing device designed 
especially for nulliparous women. However, it associates an increased risk of expulsion in the 
first 3 months. Both GyneFix and T380A are reported to have high efficiency in women con-
traception [14].
Besides pure copper devices, there is also a gold IUD called Eurogine Gold T, Goldlily, or 
GoldringMedusa, with a gold core that prevents the copper from fragmenting or corroding 
[15].
Silver was also being added on a copper device, to reduce fragmentation, and to prolong the 
lifespan of the device. The production of the initial NovaT200 was ceased, because of poorer 
performance and NovaT 380 was developed [12].
To reduce side effects of IUDs such as bleeding, pain, and expulsion, Flexi-T300 was intro-
duced, with a smaller and more flexible frame and thinner side arms that are bent back on 
themselves. Flexi-T300 is also preferred for emergency contraception, as it is cheap and easily 
inserted and removed [12].
Since 1976, medicated or hormonal IUDs were developed. Mirena was produced in 2001 as a 
hormonal IUD releasing 52 mg of levonorgestrel during a 5 years’ period of approved use 
[7]. Mirena releases approximately 20 μg of levonorgestrel daily in the first few weeks with a 
decrease to 18 μg/day by the end of 1 year and 10 μg/day after 5 years [16]. Other hormonal 
IUDs, as Skyla or Jaydess, have a shorter period of use (3 years) because of the lower levo-
norgestrel content (13.5 mg), that is released 14 μg daily after the first few weeks and with 
a rapid decrease to 10 μg/day by 2 months and 5 μg/day by the end of 3 years [17]. Besides 
contraception, the hormonal IUDs reduce the blood flow with amenorrhea in about 20% of 
cases within 1 year [18]. FibroPlant is a frameless levonorgestrel-releasing IUD with a non-
resorbable thread through the center and with similar effects on uterine-bleeding patterns as 
Mirena [12].
Other IUDs include the copper indomethacin type, available in China, with a silicone elastomer 
beads containing 25 mg of indomethacin that does not interfere with the copper release and 
reduces the menstrual cramping [12].
In Austria and Israel, a copper intrauterine ball is available, which once inserted takes the shape 
of a sphere. The rationale of the ball shape is to reduce the irritating effect of classic copper 
IUD. It is also easy to insert with no uterine perforation reported and highly accepted by 
patients [19].
New IUDs, such as flexible VeraCept—that utilize a low-dose copper configuration of 175 mm2 
surface area on a shape memory Nitinol frame—need clinical trials for validation of efficacy 
and tolerability [20] (Figures 1 and 2).
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4. IUDs mechanism of action
Both copper and hormonal IUDs involve multiple mechanisms that provide contraceptive protec-
tion. The major described effect is represented by the induction of a local inflammatory reaction in the 
Figure 1. Various types of IUD. Copper devices presented in the upper row, from left to right: T Safe Cu380A®, Nova 
T380®, Flexi-T300®, Multiload Cu375®, GyneFix®, Ocon® Cooper intrauterine ball. In the middle row—hormonal IUDs: 
Mirena®, Skyla®, FibroPlant® frameless levonorgestrel-releasing device. In the lower row, other IUD types are presented, 
as the indomethacin-releasing cooper device AiMu® and the flexible, low copper dose VeraCept®.
Figure 2. General structure with stems, arms, and strings of the IUD. Normal location after proper IUD insertion in the 
middle of the endometrial cavity with no extension in the myometrium, both arms spread toward the uterine horns and 
the inferior part of the vertical body stem just above the isthmus.
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endometrium. Therefore, the endometrial and myometrial function is disturbed by cellular and 
humoral immune-inflammatory reaction. Intrauterine foreign bodies are known to interfere with 
reproduction in all species [21]. Other mechanisms of action for copper IUDs are related to copper 
ions’ effect on the sperm motility and viability and also to changes of the cervical mucus [7]. However, 
recent studies demonstrated no significant increase in inflammatory reaction, so the effect of cop-
per on the sperm or oocyte remains as the main mechanism of action [22]. The mechanism of inhib-
iting fertilization or sperm viability impairment may be responsible for the high efficacy of copper 
IUDs as emergency contraception [23]. The reported failure rate for copper IUD placement for 
emergency contraception within 5 days of intercourse or ovulation is less than 1‰, significantly 
more effective than any hormonal emergency contraceptive [24, 25]. Even if copper IUDs do not 
usually influence the menstrual frequency or quantity, 10–13% of women have their IUD removed 
in the first year due to increase of menstrual flow and cramping-type abdominal pain [26].
Besides the foreign body reaction, another mechanism of the hormonal IUD is represented by the 
release of small amount of progestin hormones, respectively, levonorgestrel. The hormonal effects 
induce an unfriendly and even fatal environment to sperm inside the uterus, with inhibition of capac-
itation, penetration, and survival [27]. Hormonal IUDs interfere with sperm motility by thickening 
cervical mucus, thus preventing the sperm to travel up into the uterus [28], while copper IUDs 
rather impair the sperm viability, with various effects as head-tail disruption [29]. A thinner endo-
metrium develops under the progesterone influence and egg implantation is affected. Also, men-
strual blood flow is reduced, thus hormonal IUDs are frequently used to treat menorrhagia [30].
We underline that IUDs, whether hormonal or non-hormonal, do not provide protection 
against sexually transmitted diseases. Still, the historical association with pelvic inflamma-
tory disease (PID) and tubal infertility is considered false [31, 32].
The indomethacin-releasing copper IUD contains a nonsteroidal anti-inflammatory agent, 
indomethacin, that do not interfere with copper ions [33, 34], aimed to reduce the menstrual 
blood flow and cramping that are frequently related by IUDs users [33] (Table 1).
Mechanisms of action Type of intrauterine device
Copper IUD Hormonal levonorgestrel IUD
Effects on sperm
Foreign body reaction with toxic changes to sperm + +
Copper ions spermicidal or cytotoxic +
Thickened cervical mucus affecting sperm motility +
Effects on fertilization
Decreased number of fertilized ova in fallopian tubes + +
Effects on the endometrium
Immune-inflammatory reaction with increased leukocytes +
Altered cytotoxic cytokine and integrin profile + +
Endometrial atrophy, decreased thickness, and secretions +
Table 1. Mechanisms of action of the main types of IUDs. Modified, Schulman et al. [35].
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5. Adverse and side effects, health benefits, and risks of IUDs
Generally, all IUDs are well tolerated with high rates of continuation in all reversible contra-
ception types [36]. All IUD types present potential side effects: uterus perforation and malpo-
sition, especially during the inserting technique; embedment and expulsion, as it is a foreign 
body, and menstrual pattern alterations (Figure 3). All patients should be counseled regard-
ing the possibility of IUD expulsion as this is the most common complication following IUD 
insertion [37].
The expulsion rate is reported to be similar for copper and hormonal IUDs, as well as in nul-
liparous versus parous women, approximately 5% [38].
Uterine perforation is rare and surgical intervention is recommended if this occurs, but this is 
not an emergency in asymptomatic cases [39]. In these patients, a new IUD placement should 
be considered after at least 4–6 weeks time interval needed for uterine wall healing [40].
A rarely reported complication is the embedment within the endometrium. This should be sus-
pected at the ultrasound (US) follow-up, or clinically, if no IUD strings are visualized at the 
cervical os or there is difficulty with removal [41].
Copper IUDs can cause menstrual pattern alterations, especially irregular, heavy and painful 
bleeding, and intermenstrual spotting or bleeding as well throughout use [42, 43].
Figure 3. IUDs complications. (A): complete uterine perforation; (B): partial uterine perforation; (C): partial embedment 
into myometrium; (D): malposition; (E): expulsion after insertion.
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Regarding the hormonal IUDs side effects, they are similar to other progestin-based contracep-
tives such as headaches, nausea, hair loss, breast tenderness, depression, decreased libido, 
and ovarian cysts [44, 45]. Also, vulvovaginitis and abdominal or pelvic pain may be experi-
enced by users of hormonal IUDs [44, 45]. On the contrary to copper IUDs, the hormonal IUDs 
usually cause amenorrhea and oligomenorrhea after 2 years of use [42, 44].
The contraindications/health risks for IUD use are current pregnancy or gestational tropho-
blastic disease, cervico-vaginitis or acute pelvic inflammatory disease, including pelvic tuber-
culosis, puerperal sepsis and recent septic abortion, uterine (cervical or endometrial) cancer, 
unexplained vaginal bleeding, and malformed uterine cavity. Other systemic contraindica-
tions include copper allergy, immunodeficiency disorders, immunosuppressive therapy, 
Wilson’s disease, acute liver disease or liver carcinoma and breast carcinoma—especially for 
hormonal IUD, multiple sexual partners for the patient or her partner.
The major health benefit of IUD is represented by the efficacy in contraception similar or bet-
ter than female sterilization. The cooper IUD failure rate is reported to be 0.8% at 1 year, while 
a failure rate for hormonal IUD is reported to be 0.1% at 1 year [46, 47]. Of great importance is 
that this efficacy is not influenced by or related to patient age, multiple medications, or medi-
cal comorbidities and does not require patient compliance [48]. IUDs can be safely placed 
immediately after abortion or 6 weeks postpartum with high contraceptive benefits [49]. 
Copper IUD is recommended as the most effective option for emergency contraception [50].
Another IUD benefit is the fact that it can be used as an adjunctive treatment modality for 
intrauterine adhesions. Several studies have shown that IUD can be beneficial in patients 
with intrauterine adhesions or Asherman’s syndrome, especially when combined with other 
ancillary treatments [51].
Other noncontraceptive benefits of IUDs include the treatment of menorrhagia, anemia, dys-
menorrhea and pelvic pain associated to endometriosis, and endometrial protection during 
hormone replacement [48]. Since 2009, when Food and Drug Administration (FDA) approved 
the hormonal IUD as treatment for heavy menstrual bleeding, hormonal IUDs became the 
most cost-effective alternative to hysterectomy/surgery for the respective patients, with 
improved hemoglobin concentration [52]. Studies report a decrease of the menstrual blood 
loss that varies between 74 and 97% at 12 months of use [53, 54]. First, an initial irregular 
bleeding pattern is noted by most users, but over time the menstrual blood loss is improved. 
In contrast with copper IUD, the hormonal IUD can also decrease dysmenorrhea [55].
In 30% of patient with deep endometriosis or adenomyosis, an improved control of chronic 
pelvic pain and dyspareunia is noted after at least 6 months of hormonal IUD use [56, 57].
As the main effect of hormonal IUDs is to decrease the local endometrial response to estrogen, 
several studies have suggested that this may lead to primary protection from endometrial 
cancer [58]. Hormonal IUDs can also be used as a component of combined hormone therapy 
in menopausal women [52].
The use of IUD contraception is considered a health benefit in special groups such as women 
with comorbidities, in postpartum, postabortion and lactating women, patients with prior 
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thromboembolic events, bleeding diathesis, or under anticoagulation. Also, IUD contracep-
tion can be a preferable option in women with uterine fibroids after uterine artery emboliza-
tion, endometrial ablation, or magnetic resonance-guided focused ultrasound.
However, the IUD does not protect from sexually transmitted diseases; therefore, caution 
must be considered when selecting IUD users.
6. Correcting misunderstandings, myths, and barriers
6.1. IUD and PID
Since the introduction of IUDs, scientists manifested a concern that this contraception method 
may cause or facilitate gynecologic infection. In fact, the relationship between IUD and PID has 
a long and controversial history dating since 1940 [59]. Moreover, in the 1970s, the reputation of 
IUD was tarnished in many countries, as the use of a Dalkon Shield IUD was linked to several 
cases of potentially fatal pelvic sepsis [60]. Today, although there is common reserve regarding 
the PID incidence in the IUD users’ population, valuable research has shown that the risk of 
PID is no greater with IUD use than the general population [61]. WHO admits a risk of six times 
greater of PID in the first 20 days after the insertion of IUD [61]. One randomized trial found 
that the hormonal IUD might provide some protection against PID when compared to the 
group of copper IUD users and the group of IUD non-users [62]. Due to this risk, prophylactic 
antibiotics were proposed before IUD insertion, especially doxycycline and/or azithromycin. 
Multiple large, randomized control studies have demonstrated that the prophylactic antibiotic 
has no significant beneficial role in reducing the risk of PID before IUD insertion [63].
6.2. IUD and tubal infertility
Tubal infertility was thought to be a consequence of IUD use. Specific research has been con-
ducted and found that the past use of copper IUD did not increase the risk of tubal infertility 
[59]. Chlamydia infection is the primary cause of PID and tubal infertility in women who use or 
do not use IUD [31]. A cervix already infected with Chlamydia was considered to be a risk fac-
tor for placing an IUD, but proved to have no association with PID on later development [64].
6.3. IUD and the risk of ectopic pregnancy
In the past, IUD was perceived as a high risk factor for ectopic pregnancies (EPs). Actually, a 
pregnancy with an IUD in situ has an increased risk of being an EP, but the absolute risk of 
any pregnancy is extremely low in the group of IUD users, much lower than in the group of 
women with no contraception method [65, 66]. Another important aspect to highlight is that a 
history of previous EP does not represent a contraindication for IUD insertion [67].
6.4. IUD in nulliparous women
Adolescents and nulliparous women represent a special group that was considered, in the 
past, not eligible for IUD contraception. Approximately half of adolescents have never heard 
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of IUD contraception [68]. What is more, approximately one-third to one-half of health pro-
viders do not offer IUD contraception method to nulliparous women due to several myths 
and misconceptions [69]. Nowadays, there is sufficient evidence to support the use of IUDs 
in the nulliparous women as a suitable contraception method, regardless of all false myths 
and misconceptions including high risk of PID, tubal infertility, EP, gynecological neoplasia, 
difficulties of the insertion technique, and IUD expulsion [70].
6.5. IUD and gynecological neoplasia
There is a lack of awareness and understanding of IUD contraception by women worldwide, possi-
bly due to lack of medical education and proper information. A frequent misconception of IUD use 
is that it increases the risk of genital cancer. Mandatory screening for cervical cancer is a require-
ment of many guidelines before IUD insertion. In fact, several epidemiological studies suggested 
that IUDs might protect against cervical carcinogenesis [71]. The role of hormonal IUD as a protec-
tive factor against endometrial hyperplasia is well known [58]. Accurate information regarding the 
use of hormonal IUD must underline the risk of ovarian cysts, but not ovarian cancer.
6.6. IUD and female sexual dysfunction
Female sexual dysfunction was thought to be determined by IUD but in fact has a multifacto-
rial etiology and studies found no difference between IUD users or non-users [72].
7. The technique of inserting and removing IUDs
IUD represents the choice method of contraception for many women as its effects are revers-
ible after removal.
The insertion technique is easy and well tolerated by selected female patients after taking into 
consideration the contraindications, as well as the health benefits for women with anemia, men-
orrhagia, or dysmenorrhea [73]. First, it is advisable to have a documentation of a negative preg-
nancy test as a precaution. Also, exclusion of a possible Chlamydia or gonorrhea is advisable 
before an IUD is inserted [74]. The insertion can be performed at any time during the menstrual 
cycle [42]. In the past, the technique was preferred to be done during menses to exclude preg-
nancy, but this is associated with a higher risk of expulsion. Several studies found that the pain 
during the insertion is lower during the sixth and the tenth days of the menstrual cycle [26]. 
Regarding the insertion of a hormonal IUD, the appropriate timing is considered to be within the 
first 5 days of menstrual bleeding or immediately after childbirth, abortion, or switching from an 
alternative contraceptive method [42, 75]. Backup contraception is recommended for a period of 
7 days after the hormonal IUD insertion and is not needed after the copper IUD insertion [48]. 
In cases of emergency contraception, the insertion of the copper IUD can be done within the 
5 days of the unprotected intercourse to prevent pregnancy [25]. The use of a hormonal IUD has 
not been yet studied and so it is not recommended for emergency contraception. The removal 
of both the copper IUD and the hormonal IUD can be performed anytime preferably during the 
menstrual cycle. As mentioned before, antibiotic prophylaxis is not needed before IUD insertion 
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or removal, even in patients at risk for endocarditis [76]. The insertion procedure is usually done 
by a trained provider in the office, and only in special circumstances, such as mentally limited 
patients and nulliparous young women, it can be done under sedation. The physician must 
discuss all risks and benefits of IUD with the patient and must obtain an informed consent. The 
use of misoprostol before IUD insertion to allow an easier procedure was proposed in 2007 [77]. 
However, more recent researches found no benefit but increased side effects with misoprostol, 
and no recommendation has been yet made [78, 79]. On the other hand, the use of a nonsteroi-
dal anti-inflammatory drug, respectively, 600–800 mg of ibuprofen 1 h before the procedure 
can alleviate discomfort [80]. Also, the physician must educate the patient in locating the IUD 
threads after each menstruation and consulting earlier if incapacity to locate [80]. IUD insertion 
is similar for copper IUD and for hormonal IUD. The preparation before IUD insertion must 
include the determination of uterus position. This can be done by a bimanual examination or 
by an ultrasound examination. All proper equipment must be sterile and assembled before the 
procedure. The cervix and vagina must be cleansed with antiseptic solution. A speculum is used 
to visualize the cervix and a tenculum to stabilize the cervix. Local anesthesia is preferred with 
lidocaine gel in the cervical canal, or a paracervical block. The uterine depth must be verified 
using a hysterometer and the IUD is inserted as shown in the accompanying written material of 
any IUD. After proper insertion, the threads should be cut to a length of 3 cm. A post-procedure 
ultrasound should be performed to verify the IUD position [81]. The removal procedure should 
be considered anytime on patient request. If any contraindication appears or adverse effects 
persist, IUD can be easily removed by grasping the threads at the external os. Special conditions 
include impossibility to remove the IUD with a simple traction; deeply embedment IUD should 
be suspected and in such cases, hysteroscopy is mandatory. Cervical screening is performed 
the same as in IUD non-users. Colposcopy is performed the same, but excisional procedure for 
cervical dysplasia must be performed after IUD removal [81].
8. The role of ultrasound in IUD users
US evaluation of the pelvis, especially transvaginally, has become an important part of the 
gynecological care and is essential for the assessment of IUD position after insertion [81]. 
Moreover, the lack of a pelvic US examination before IUD insertion may predispose to mal-
position or serious complications such as perforation [82]. US assessment is cheap, easy to 
learn, perform and interpret, efficient, and without side effects [81]. A correct positioned IUD 
is visualized in the middle of the endometrial cavity with no extension in the myometrium, 
with both arms spread toward the uterine horns and the inferior part of the vertical body of 
the IUD just above the isthmic portion of the uterus [83] (Figure 4). The two-dimensional tech-
nique has some limits in the evaluation of the IUD position, as the most important plane for 
this purpose, the coronal plane, usually cannot be imagined. Three-dimensional (3D) assess-
ment is also helpful to identify hormonal IUD, because of the lack of echogenicity (Figure 4B), 
unlike copper IUD that are easily identified due to its high echogenity.
About 10% of IUDs are malpositioned and so the efficacy in contraception is significantly 
decreased. More than half of the patients with a malpositioned IUD are asymptomatic. Still, 
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there are no general guidelines for a routine transvaginally US verification after IUD inser-
tion [84]. The 3D US technique has the advantage to allow subsequent reconstruction of 
the coronal plane [83]. This approach provides a correct diagnosis regarding the malposi-
tion, expulsion, displacement, embedment, or perforation (Figure 5). It can also detect more 
specifically uncommon complications such as fragmentation and calcification [81]. So, 3D 
has become crucial as it is more sensitive in assessing symptomatic IUD users, but also 
for routine evaluation. However, familiarity with the transvaginal 2D/3D US techniques is 
essential.
Figure 4. Ultrasound image of hormonal IUD. (A) 2D image; (B) 3D rendering, with reconstruction of the coronal plane.
Figure 5. Ultrasound image of a malpositioned copper IUD. (A) 2D image; (B) 3D rendering of the coronal plane showing 
copper IUD displacement; (C) 3D rendering showing copper IUD partial embedment into myometrium.
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9. Management of problems in continuing users
Patient satisfaction and acceptability are extremely important regardless of their contracep-
tive method. After a proper counseling regarding the risks and the benefits, women choose 
the appropriate most effective contraception option to prevent an undesired pregnancy. The 
continuation rates for copper IUD are reported to be as high as 84% at 12 months and 85% for 
hormonal IUD [85]. Overall, the satisfaction rates of women users of IUDs are the highest 
between all other contraceptive methods [86]. In terms of IUDs advantages, the most fre-
quently reported reasons are the ease of use, efficacy, and reliability, but also reduction of the 
menstrual flows when using a hormonal IUD [40].
Pelvic pain is the most frequent side effect of any IUDs. Approximately 27% of copper IUD 
users and 34% of hormonal IUD users have their IUD removed prior to 6 months because 
of continuing cramping [87]. The post-insertion pain can be managed with 400 mg of ibu-
profen/325–650 mg of aspirin/325–1000 mg of paracetamol/200 mg of naproxen. The post-
insertion recommendations forbid tampons, vaginal douching, and sex for 24 h [48].
Another reason for discontinuation is represented by irregular bleeding patterns especially for 
hormonal IUD users. With the copper IUDs, most women continue to have regular monthly 
periods and bleeding may get heavier [48]. In such cases, tranexamic acid can be required for a 
short-term relief, but unfortunately, it is not available in many countries. Another option may 
be nonsteroidal anti-inflammatory drugs, such as indomethacin, but not aspirin. Anemia may 
be a serious side effect of using copper IUD, so patients must receive iron tablets for the anemia 
prevention or indication to a specific diet rich in foods containing iron. Amenorrhea is a com-
mon side effect when using hormonal IUD. Even if irregular bleeding may bother the user, the 
menstrual flow is overall decreased [88]. In adolescents, a 7% rate of discontinuation has been 
reported within the first year, independent to the IUD type, due to abnormal bleeding [89].
Most cases of discontinuation can be prevented by an accurate medical informed discussion 
between the user and the health provider prior to IUD insertion. Both types of IUD should be 
taken into consideration and the best decision must consider the benefits, but also all adverse 
effects. The most important disadvantage of IUD use is the fact that it does not offer protection 
from sexually transmitted diseases and condom should be used for this purpose. In rare cases, 
the male partner can feel the IUD retrieval strings or stem during intercourse and this may 
bother him. Strings can be cut shorter or in some cases the IUD can be removed and a new one 
inserted. Lack of medical education seems to be the main cause for the reduced uptake and 
continuation rates for intrauterine contraception among female patients [90].
10. When to switch to other contraception methods
Other contraception methods should be considered if menstrual bleeding is increased when 
using copper IUDs or if irregular bleeding induced by using the hormonal IUDs becomes a 
disturbance in the female patient’s routine.
PID or EP represents a cause for severe pain in the lower abdomen. However, PID does not rep-
resent an indication to remove the IUD before starting antibiotic treatment. If EP is diagnosed, 
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IUD must be removed and proper specific treatment should be initiated. IUD should be removed 
also in intrauterine pregnancy cases. If the woman wants to terminate the pregnancy, the removal 
procedure is done before the evacuation of the uterus. If the woman wants to continue the preg-
nancy, early removal of the IUD reduces the risk of preterm delivery or miscarriage.
During the insertion procedure, perforation may be suspected. In such situations, immediate 
removal of the IUD is recommended along continuous monitoring of the patient’s vital signs. 
If perforation is suspected after 6 weeks of insertion or later, then the IUD should be removed 
by an experienced clinician and other contraception method should be considered.
If the IUD is partially expelled, it must be removed and insertion of a new one should be 
decided with the patient after careful counseling. If the IUD is completely expelled, then other 
contraceptive methods are advisable.
Male discomfort during intercourse is a rare cause for switching to other contraception methods.
11. New alternative to IUD
A series of medical conditions, due to high maternal mortality rates approaching 50%, rep-
resent an imperative indication for the most reliable methods of contraception in women. 
Essure was introduced in 2002 as a new sterilization method for women who do not desire to 
preserve fertility or for those who have significant medical contraindications. Essure is com-
posed of two intra-tubal stents that must be inserted into the proximal section of the fallopian 
tube. This procedure is done hysteroscopically using only oral analgesia or sedation [91]. The 
contraceptive effect is installed in 3 months after insertion due to mechanical obstruction and 
inflammation causing fibrosis [92]. Thus, an additional form of contraception must be used 
in the meantime other than IUD. The main advantages of Essure are represented by the fact 
that Essure is non-incisional, permanent birth control device [93]. The insertion procedure 
is ideally performed in the proliferative phase when the tubal ostia can be easily visualized 
and cannulated. Tubal stenosis and tubal spasm can determine the failure of placement, but 
also poor visualization [94]. The procedure success rate varies from 85 to 98% [95]. When 
inserted, there is a risk of vaso-vagal attacks of 1.85% [96]. The Essure contraindications are 
the uncertainty regarding ending fertility, suspected pregnancy, active or recent PID, uterine 
anomalies, less than a 6-week interval after delivery or miscarriage, patient unwilling to use 
other contraceptive methods for the first 3 months, prior tubal ligation, and current immu-
nosuppressive therapy [97]. After 3 months post-insertion, an imaging method to verify the 
position of the Essure is recommended. Several studies have been done in order to establish 
the best imaging method between hysterosalpingogram (HSG), X-ray, or hysterosalpingo-
contrast sonography. Still, all studies underline the importance of trained staff in assess-
ing the appropriate Essure placement [93] (Figure 6). As complications, mild pain has been 
reported in most cases—80% of patients, while severe pain may be encountered in 17% [98]. 
Also, minor symptoms like cramping, nausea, and light bleeding or spotting can also occur in 
the first week [3]. Severe complications like tubal perforation and expulsion are rare. Essure is 
compatible with 1.5 T of magnetic resonance imaging (MRI), but special caution is indicated 
in 3 T MRI and with some techniques of endometrial ablation. In terms of efficacity, Essure 
has a 99.74% successful rate in permanent contraception after 5 years [97]. The minimal risk of 
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pregnancy with Essure can be overcome by educating patients to respect the recommended 
instructions and comply to periodic follow-ups, including HSG protocol [98].
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